Ganirelix (acetate)

Ganirelix acetate (Ganirest) is an injectable competitive gonadotropin-releasing hormone (GnRH) antagonist. Ganirelix acetate directly competes against the endogenous molecule for receptor binding, and causes a rapid reduction in estradiol levels. Ganirelix acetate can be used for researching ovarian hyperstimulation syndrome (OHSS) [1].

Product Specifications

CAS Number

[129311-55-3]

Product Name Alternative

Ganirest

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

GnRH Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/ganirelix-acetate.html

Purity

99.19

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

OC(C=C1)=CC=C1C[C@H](NC([C@H](CO)NC([C@@H](CC2=CN=CC=C2)NC([C@H](NC([C@H](NC(C)=O)CC3=CC4=CC=CC=C4C=C3)=O)CC5=CC=C(Cl)C=C5)=O)=O)=O)C(N[C@H](CCCC/N=C(NCC)/NCC)C(N[C@@H](CC(C)C)C(N[C@@H](CCCC/N=C(NCC)/NCC)C(N6[C@@H](CCC6)C(N[C@H](C)C(N)=O)=O)=O)=O)=O)=O.CC(O)=O.CC(O)=O

Molecular Formula

C84H121ClN18O17

Molecular Weight

1690.42

Precautions

H315, H319, H335

References & Citations

[1]Gustofson RL, et al. Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome. Hum Reprod. 2006 Nov;21 (11) :2830-7.